Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab) has shown continued benefit over four years, according ...

A health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese ...

TOKYO, July 25, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has been included in the FTSE4Good Index Series for the 24th ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years into treatment, according to new data presented at a medical meeting on ...

Eisai intends for the drug to be injected into fleshy parts of the body, such as the stomach or thighs. The number of injections and doses are still under consideration.

Eisai unveiled much-anticipated findings on its experimental Alzheimer’s drug, providing tinder for the hot debate over whether its modest efficacy is worth potential risks that include serious ...

SAN FRANCISCO--An experimental Alzheimer’s disease drug from Eisai and Biogen slowed cognitive decline in a closely watched trial but may carry a risk of dangerous side effects for certain ...

TOKYO, May 23, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) ...

TOKYO -- Japanese drugmaker Eisai said Wednesday it will invest up to $15 million in C2N Diagnostics, a U.S. biotechnology firm that has developed a blood test for early signs of Alzheimer's disease.

TOKYO, March 4 (Reuters) - Eisai Co <4523.T>, Japan's No.4 drugmaker, said it expects annual U.S. sales of its flagship Alzheimer's drug Aricept to fall 60 percent in three years, hit by the ...

In March 2018, Eisai and Merck & Co., Inc., Rahway, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.

Review the current Eisai Co Ltd (4523:XTKS) dividend yield and history to decide if 4523 is the best investment for you.